Net l oss for the first nine months of 20 23 decreased by 44% as compared to the same period in 2022 Cash resources of $390.2 million as of September 30, 2023 expected to fund planned operations through at least the end of 2026, and potentially beyond Updated clinical results from Phase 1b/2 study
Continue Reading
Net loss for the first six months of 2023 decrease d by 45% as compared to the same period in 2022 Cash resources of $431.4 million as of June 30, 2023 expected to fund planned operations through at least the end of 2026, and potentially beyond Presented full clinical results from Phase 2b study of
Continue Reading
Confirmed prior guidance on 2023 operating cash burn of between $90 and $120 million and cash runway through at least 2026, and potentially beyond Net quarterly loss decreased by 66% to $24.4 million as compared to first quarter in 2022 Presented 11 posters at the American Association for Cancer
Continue Reading
2022 was a year of transformation and change: reported $412.5 million in total revenue for the year ended December 31, 2022 ; reported net income of $124.3 million ( $1.90 per fully diluted share) for 2022 compared to net loss of $211.8 million in 2021; reported $492.2 million in cash resources as
Continue Reading
